Burden of epilepsy in Latin America and The Caribbean: a trend analysis of the Global Burden of Disease Study 1990 - 2019.
Burden of disease
epidemiology (source: MESH)
epilepsy
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
13
2
2023
pubmed:
16
12
2021
medline:
16
12
2021
Statut:
epublish
Résumé
The epilepsy prevalence in Latin America and the Caribbean (LAC) had remained high over the last 20 years. Data on the burden of epilepsy are needed for healthcare planning and resource allocation. However, no systematic analysis had been performed for epilepsy burden in LAC. We extracted data of all LAC countries from the Global Burden of Disease (GBD) study from 1990 to 2019. Epilepsy burden was measured as prevalence, mortality, and disability-adjusted life-years (DALYs; defined by the sum of years of life lost [YLLs] for premature mortality and years lived with disability [YLDs]), by age, sex, year, and country. Absolute numbers, rates, and 95% uncertainty intervals were reported. We performed correlational analyses among burden metrics and Socio-demographic Index (SDI). The burden of epilepsy decreased around 20% in LAC, led by YLLs reduction. In 2019, 6·3 million people were living with active epilepsy of all causes (95% UI 5·3 - 7·4), with 3·22 million (95% UI 2·21 - 4·03) and 3·11 million (95% UI 2·21 to 4·03) cases of epilepsy with identifiable aetiology and idiopathic epilepsy, respectively. The number of DALYs represented the 9·51% (1.37 million, 95% UI 0·99 -1·86) of the global epilepsy burden in 2019. The age-standardized burden was 175·9 per 100 000 population (95% UI 119·4 - 253·3), which tend to have a bimodal age distribution (higher in the youth and elderly) and was driven by high YLDs estimates. The burden was higher in men and older adults, primarily due to high YLLs and mortality. Alcohol use was associated with 17% of the reported DALYs. The SDI estimates significantly influenced this burden (countries with high SDI have less epilepsy burden and mortality, but not prevalence or disability). The epilepsy burden has decreased in LAC over the past 30 years. Even though, LAC is still ranked as the third region with the highest global epilepsy burden. This reduction was higher in children, but burden and mortality increased for older adults. The epilepsy burden is disability predominant; however, the mortality-related estimates are still higher than in other regions. Alcohol consumption and countries' development are important determinants of this burden. There is an urgent need to improve access to epilepsy care in LAC, particularly for older adults. Strengthening primary care with online learning and telemedicine tools, and promoting risk factors modification should be prioritized in the region. This research was self-funded by the authors.
Sections du résumé
Background
UNASSIGNED
The epilepsy prevalence in Latin America and the Caribbean (LAC) had remained high over the last 20 years. Data on the burden of epilepsy are needed for healthcare planning and resource allocation. However, no systematic analysis had been performed for epilepsy burden in LAC.
Methods
UNASSIGNED
We extracted data of all LAC countries from the Global Burden of Disease (GBD) study from 1990 to 2019. Epilepsy burden was measured as prevalence, mortality, and disability-adjusted life-years (DALYs; defined by the sum of years of life lost [YLLs] for premature mortality and years lived with disability [YLDs]), by age, sex, year, and country. Absolute numbers, rates, and 95% uncertainty intervals were reported. We performed correlational analyses among burden metrics and Socio-demographic Index (SDI).
Findings
UNASSIGNED
The burden of epilepsy decreased around 20% in LAC, led by YLLs reduction. In 2019, 6·3 million people were living with active epilepsy of all causes (95% UI 5·3 - 7·4), with 3·22 million (95% UI 2·21 - 4·03) and 3·11 million (95% UI 2·21 to 4·03) cases of epilepsy with identifiable aetiology and idiopathic epilepsy, respectively. The number of DALYs represented the 9·51% (1.37 million, 95% UI 0·99 -1·86) of the global epilepsy burden in 2019. The age-standardized burden was 175·9 per 100 000 population (95% UI 119·4 - 253·3), which tend to have a bimodal age distribution (higher in the youth and elderly) and was driven by high YLDs estimates. The burden was higher in men and older adults, primarily due to high YLLs and mortality. Alcohol use was associated with 17% of the reported DALYs. The SDI estimates significantly influenced this burden (countries with high SDI have less epilepsy burden and mortality, but not prevalence or disability).
Interpretation
UNASSIGNED
The epilepsy burden has decreased in LAC over the past 30 years. Even though, LAC is still ranked as the third region with the highest global epilepsy burden. This reduction was higher in children, but burden and mortality increased for older adults. The epilepsy burden is disability predominant; however, the mortality-related estimates are still higher than in other regions. Alcohol consumption and countries' development are important determinants of this burden. There is an urgent need to improve access to epilepsy care in LAC, particularly for older adults. Strengthening primary care with online learning and telemedicine tools, and promoting risk factors modification should be prioritized in the region.
Funding
UNASSIGNED
This research was self-funded by the authors.
Identifiants
pubmed: 36778734
doi: 10.1016/j.lana.2021.100140
pii: S2667-193X(21)00136-8
pmc: PMC9904123
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100140Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare to have no compelling interests in this article.
Références
Lancet. 2021 Apr 10;397(10282):1375-1386
pubmed: 33838758
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Health Aff (Millwood). 2015 Oct;34(10):1704-12
pubmed: 26438747
Lancet Neurol. 2007 Aug;6(8):693-8
pubmed: 17611160
Popul Dev Rev. 2011;37(Suppl 1):143-57
pubmed: 21280368
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
J Neurosci Rural Pract. 2020 Apr;11(2):287-290
pubmed: 32367985
Epileptic Disord. 2018 Oct 1;20(5):386-395
pubmed: 30378539
Neurology. 2018 Feb 27;90(9):e779-e789
pubmed: 29386275
Epilepsia. 1985 May-Jun;26(3):268-78
pubmed: 3924589
PLoS Negl Trop Dis. 2013 Oct 31;7(10):e2480
pubmed: 24205415
Bull World Health Organ. 2010 Apr;88(4):260-6
pubmed: 20431789
Am J Med Genet. 2001 Summer;106(2):139-45
pubmed: 11579434
Lancet. 2020 Feb 29;395(10225):735-748
pubmed: 32113502
Lancet. 2020 Oct 17;396(10258):1135-1159
pubmed: 33069324
Epilepsy Behav. 2020 Sep;110:107164
pubmed: 32480303
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Psychol Res Behav Manag. 2013 Oct 21;6:111-6
pubmed: 24174885
Addiction. 2017 Jun;112(6):968-1001
pubmed: 28220587
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Int J Ment Health Syst. 2019 May 29;13:36
pubmed: 31160920
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Epilepsia. 2016 Jan;57 Suppl 1:4-16
pubmed: 26749012
Epilepsia. 2021 Apr;62(4):984-996
pubmed: 33651439
AMIA Jt Summits Transl Sci Proc. 2019 May 06;2019:163-172
pubmed: 31258968
Epilepsia. 2017 Nov;58(11):1955-1961
pubmed: 28850668
Int J Equity Health. 2019 Oct 15;18(1):156
pubmed: 31615530
Epilepsy Behav. 2016 Feb;55:108-12
pubmed: 26773679
Pharmacol Biochem Behav. 2017 Jan;152:97-104
pubmed: 27424276
Seizure. 2015 Feb;25:99-103
pubmed: 25458096
Drug Alcohol Depend. 2015 Nov 1;156:1-13
pubmed: 26371405
Lancet. 2015 Mar 28;385(9974):1230-47
pubmed: 25458725
Parasit Vectors. 2017 Sep 18;10(1):424
pubmed: 28923090
Seizure. 2009 Dec;18(10):665-71
pubmed: 19819737
Lancet Neurol. 2019 Apr;18(4):357-375
pubmed: 30773428
Neurosci Lett. 2021 Apr 17;750:135753
pubmed: 33610673
Birth. 2005 Sep;32(3):210-8
pubmed: 16128976
Epilepsia. 2011 Sep;52 Suppl 7:2-26
pubmed: 21899536
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Neurology. 2017 Jan 17;88(3):296-303
pubmed: 27986877
J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):349-51
pubmed: 14966142
Epilepsy Behav. 2010 Jan;17(1):46-9
pubmed: 19910261
Epilepsia. 1979 Dec;20(6):729-37
pubmed: 499118
J Intellect Disabil Res. 2014 Jun;58(6):508-20
pubmed: 23647577
Seizure. 2016 Dec;43:56-60
pubmed: 27886630
PLoS Negl Trop Dis. 2015 Nov 18;9(11):e0004236
pubmed: 26580210
Lancet. 2009 Jul 18;374(9685):187-9
pubmed: 19623681
Early Hum Dev. 2010 Jun;86(6):329-38
pubmed: 20554402
Anthropol Anz. 2006 Sep;64(3):311-9
pubmed: 17128934
Epilepsia. 2021 May;62(5):1158-1169
pubmed: 33734434
Epilepsy Behav. 2020 Jan;102:106724
pubmed: 31816480
Seizure. 2010 Jul;19(6):363-7
pubmed: 20554456
Health Syst Reform. 2018;4(3):203-213
pubmed: 30067439
Int J Infect Dis. 2019 Aug;85:37-48
pubmed: 31085314
Lancet. 2019 Feb 16;393(10172):689-701
pubmed: 30686584
Front Neurol. 2021 Apr 16;12:643450
pubmed: 33935942
Neurology. 2020 Jan 28;94(4):e419-e429
pubmed: 31831600
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326